Press

Press

2020-02-20 08:00 Successful rights issue enables increased focus on strategic initiatives Regulatory MAR
2020-02-18 13:00 Första patienten inkluderad i den nya kliniska studien FILTER-SCAD med sammanlagt 2 000 patienter
2020-02-18 13:00 First patient enrolled in the new clinical study FILTER-SCAD targeting 2,000 patients
2020-01-14 10:00 First patients with the CADScor®System in the UK
2020-01-14 10:00 Första patienterna utvärderas med CADScor®System i Storbritannien
2019-12-20 08:09 Acarix AB: Redeye initiates coverage of Acarix
Redeye initiates coverage of Acarix. The company's significant potential hinges on its CADScor system's invention of coronary artery disease (CAD) testing...
2019-12-16 10:00 Acarix submits FDA application
2019-12-16 10:00 Acarix lämnar in FDA-ansökan
2019-11-14 08:00 Acarix AB (publ) publishes Interim Report, January – September 2019 Regulatory MAR
2019-11-14 08:00 Acarix AB (publ) publicerar delårsrapport, januari – september 2019 Regulatory MAR
2019-10-30 08:30 Acarix announce final outcome in rights issue Regulatory
2019-10-30 08:30 Acarix offentliggör slutgiltigt utfall i företrädesemission Regulatory
2019-10-09 09:09 Idag inleds teckningsperioden i Acarix företrädesemission Regulatory
2019-10-09 09:09 The subscription period in Acarix' rights issue commence today Regulatory
2019-09-30 13:43 Acarix publish EU growth prospectus in connection with rights issue of up to approximately SEK 51.8 million Regulatory
2019-09-30 13:43 Acarix offentliggör EU-tillväxtprospekt i samband med företrädesemission om cirka 51,8 MSEK Regulatory
2019-09-25 08:30 Acarix genomför företrädesemission om cirka 51,8 MSEK för att finansiera ökad marknadsexpansion Regulatory MAR
2019-09-25 08:30 Acarix carries out a rights issue of approximately SEK 51.8 million to finance an increased market expansion Regulatory MAR
2019-08-16 13:22 Announcement from Acarix's extra general meeting Regulatory
2019-08-16 13:22 Kommuniké från extra bolagsstämma i Acarix Regulatory
2019-08-06 08:00 Acarix AB (publ) publicerar delårsrapport, januari – juni 2019 Regulatory MAR
2019-08-06 08:00 Acarix AB (publ) publishes Interim Report, January – June 2019 Regulatory MAR
2019-08-05 12:30 CADScor®System – Significantly more effective than current practice
2019-08-05 12:30 CADScor®System – Betydligt effektivare än nuvarande metoder
2019-07-17 08:00 Kallelse till extra bolagsstämma i Acarix AB Regulatory
2019-07-17 08:00 Notice of extra general meeting in Acarix AB Regulatory
2019-06-27 10:31 Acarix CADScor®System – nu inkluderad i NICEs riktlinjer för vård och hälsa
2019-06-27 10:31 Acarix CADScor®System included in NICE guidelines (UK)
2019-06-07 08:43 Acarix participates on the Redeye Growth Day, Monday 10 June 2019
2019-06-07 08:43 Acarix presenterar på Redeye Growth Day, 10 juni 2019
PreviousNext

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based Coronary Artery Disease (CAD) rule-out.

The CE-mark approved and FDA De Novo cleared Acarix CADScor®System is for patients experiencing stable chest pain with suspected CAD and is designed to help reduce millions of unnecessary and costly diagnostic procedures.2 CADScor®System calculates a patient-specific CAD-score non-invasively in 10 minutes with at least 96% confidence (Negative Predictive Value).¹

Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX).

Learn more
  1. User manual US-FDA v.12.Y, prevalence 10,7%
  2. Shaw LJ, Marwick TH, Zoghbi WA, Hundley WG, Kramer CM, Achenbach S, Dilsizian V, Kern MJ, Chandrashekhar Y, Narula J. Why all the focus on cardiac imaging? JACC Cardiovasc Imaging. 2010 Jul;3(7):789-94. doi: 10.1016/j.jcmg.2010.05.004. PMID: 20633864.